Evidence map›Paper›PMID 32667957›Full record

ArticlePloS one2020

Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.

Ganbolor Jargalsaikhan, Miriam Eichner, Delgerbat Boldbaatar, Purevjargal Bat-Ulzii, Oyungerel Lkhagva-Ochir, Odgerel Oidovsambuu, Bekhbold Dashtseren, Erdenebayar Namjil, Zulkhuu Genden, Dahgwahdorj Yagaanbuyant and 6 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ganbolor JargalsaikhanLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Miriam EichnerLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Delgerbat BoldbaatarLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Purevjargal Bat-UlziiLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Oyungerel Lkhagva-OchirLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Odgerel OidovsambuuLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Bekhbold DashtserenLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Erdenebayar NamjilNational Center of Transfusion Medicine, Sukhbaatar District, Ulaanbaatar, Mongolia.
Zulkhuu GendenLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Dahgwahdorj YagaanbuyantLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Alimaa TuyaNational Center of Transfusion Medicine, Sukhbaatar District, Ulaanbaatar, Mongolia.
Naran GurjavNational Center of Transfusion Medicine, Sukhbaatar District, Ulaanbaatar, Mongolia.
Altankhuu MordorjLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Andreas BungertLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.ORCID 0000-0003-1515-7759
Naranbaatar DashdorjLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
Naranjargal DashdorjLiver Center, Sukhbaatar District, Ulaanbaatar, Mongolia.
National Center for Communicable Diseases · MNMongolian National University of Medical Sciences · MNNational University of Mongolia · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is pivotal for optimal disease management. Sensitivity and specificity of 19 rapid diagnostic test (RDT) kits by different manufacturers (ABON, CTK Biotech, Cypress Diagnostics, Green Gross, Human Diagnostic, Humasis, InTec, OraSure, SD Bioline, Wondfo) were assessed on serum samples of 270 Mongolians (90 seropositive for hepatitis B surface antigen (HBsAg), 90 seropositive for hepatitis C antibody (HCV-Ab), 90 healthy subjects). All tested RDTs for detection of HBsAg performed with average sensitivities and specificities of 100% and 99%, respectively. Albeit, overall sensitivity and specificity of RDTs for detection of HCV-Ab was somewhat lower compared to that of HBsAg RDTs (average sensitivity 98.9%, average specificity 96.7%). Specificity of RDTs for detection of HCV-Ab was dramatically lower among HBsAg positive individuals, who were 10.2 times more likely to show false positive test results. The results of our prospective study demonstrate that inexpensive, easy to handle RDTs are a promising tool in effective HBV- and HCV-screening especially in resource-limited settings.

Indexed as

AdolescentAdultAgedFemaleHepatitis BHepatitis B Surface AntigensHepatitis CHepatitis C AntibodiesHumansMaleMass ScreeningMiddle AgedProspective StudiesReagent Kits, DiagnosticSensitivity and SpecificityHepatitis B Surface AntigensHepatitis C AntibodiesReagent Kits, Diagnostic

Identifiers

PMID32667957
PMCPMC7363090
OpenAlexW3042824621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.